Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.

ABSTRACT:

Introduction

Alterations in the MET gene, including amplifications and exon 14 skipping mutations, have been identified as actionable oncogenic alterations. However, MET fusions are rarely detected in lung cancer, and their sensitivity to therapeutics has not been systematically analyzed.

Methods

The data from 30876 lung cancer patients from the LAVA database and 7966 patients from cBioPortal database were screened. Basic demographic and clinical information for the patients harboring MET fusions were collected. A lung squamous cell cancer patient harboring a novel EML4-MET fusion was treated with crizotinib. Additionally, a literature review was performed to summarize the cases of patients harboring MET fusions and their treatment information.

Results

MET fusions wer

SUBMITTER: Sun D 

PROVIDER: S-EPMC9960416 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature